Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait
Authors:
- 6 April 2021
- journal article
- research article
- Published by Taylor & Francis in Immunotherapy
- Vol. 13 (8) , 637-644
Abstract
Advanced hepatocellular carcinoma (HCC) patients present poor prognosis. However, recent years have seen the advent of several novel treatments in this setting, where the role of immune checkpoint ...Keywords
This publication has 47 references indexed in Scilit:
- Pembrolizumab as First-Line Therapy for Metastatic Non-Small-Cell Lung CancerImmunotherapy, 2017
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical OutcomeFrontiers in Pharmacology, 2017
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialThe Lancet, 2017
- Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Angiogenesis, 2017
- Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial CarcinomaClinical Pharmacology & Therapeutics, 2016
- Coinhibitory Pathways in Immunotherapy for CancerAnnual Review of Immunology, 2016
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitormAbs, 2016
- Rationally Combining Anti-VEGF Therapy with Checkpoint Inhibitors in Hepatocellular CarcinomaImmunotherapy, 2016
- Novel drugs in clinical development for hepatocellular carcinomaExpert Opinion on Investigational Drugs, 2015
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012